Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D309/10—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
  • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen

Definitions

• the invention relates to a crystalline hydrate and to crystalline complexes of 1-chloro-4-( ⁇ - D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, to methods for the preparation thereof, as well as to the use thereof for preparing medicaments.
• compound A The compound 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene (in the following referred to it as "compound A”) is described in the international patent application WO 2005/092877 and has the chemical structure according to formula A
• the compounds described therein have a valuable inhibitory effect on the sodium-dependent glucose cotransporter SGLT, particularly SGLT2.
• the method of manufacture of the compound A as described therein does not yield a crystalline form.
• a certain phamaceutical activity is of course the basic prerequisite to be fulfilled by a pharmaceutically active agent before same is approved as a medicament on the market.
• a pharmaceutically active agent has to comply with. These requirements are based on various parameters which are connected with the nature of the active substance itself. Without being restrictive, examples of these parameters are the stability of the active agent under various environmental conditions, its stability during production of the pharmaceutical formulation and the stability of the active agent in the final medicament compositions.
• the pharmaceutically active substance used for preparing the pharmaceutical compositions should be as pure as possible and its stability in long-term storage must be guaranteed under various environmental conditions. This is essential to prevent the use of pharmaceutical compositions which contain, in addition to the actual active substance, breakdown products thereof, for example.
• the content of active substance in the medicament might be less than that specified.
• Uniform distribution of the medicament in the formulation is a critical factor, particularly when the medicament has to be given in low doses.
• the particle size of the active substance can be reduced to a suitable level, e.g. by grinding. Since breakdown of the pharmaceutically active substance as a side effect of the grinding (or micronising) has to be avoided as far as possible, in spite of the hard conditions required during the process, it is essential that the active substance should be highly stable throughout the grinding process. Only if the active substance is sufficiently stable during the grinding process it is possible to produce a homogeneous pharmaceutical formulation which always contains the specified amount of active substance in a reproducible manner.
• Another problem which may arise in the grinding process for preparing the desired pharmaceutical formulation is the input of energy caused by this process and the stress on the surface of the crystals. This may in certain circumstances lead to polymorphous changes, to amorphization or to a change in the crystal lattice. Since the pharmaceutical quality of a pharmaceutical formulation requires that the active substance should always have the same crystalline morphology, the stability and properties of the crystalline active substance are subject to stringent requirements from this point of view as well.
• the stability of a pharmaceutically active substance is also important in pharmaceutical compositions for determining the shelf life of the particular medicament; the shelf life is the length of time during which the medicament can be administered without any risk. High stability of a medicament in the abovementioned pharmaceutical compositions under various storage conditions is therefore an additional advantage for both the patient and the manufacturer.
• compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture.
• a pharmaceutically active substance should be only slightly hygroscopic.
• the aim of the invention is thus to provide a new, stable crystalline form of the compound A which meets important requirements imposed on pharmaceutically active substances as mentioned above.
• the present invention relates to a crystalline complex between one or more natural amino acids and 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene.
• a second aspect of the present invention relates to a pharmaceutical composition or medicament comprising one or more crystalline complexes as defined hereinbefore and hereinafter.
• the present invention relates to a crystalline hydrate of 1-chloro-4-( ⁇ -D- glucopyranos-1 -yl)-2-(4-ethynyl-benzyl)-benzene.
• a fourth aspect of the present invention relates to a pharmaceutical composition or medicament comprising one or more crystalline hydrates as defined hereinbefore and hereinafter.
• the present invention relates to a use of one or more crystalline complexes or crystalline hydrates as defined hereinbefore or hereinafter for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be influenced by inhibiting sodium-dependent glucose cotransporter SGLT, preferably SGLT2.
• the present invention relates to a use of one or more crystalline complexes or crystalline hydrates as defined hereinbefore or hereinafter for preparing a pharmaceutical composition which is suitable for the treatment or prevention of metabolic disorders.
• the present invention relates to a use of one or more crystalline complexes or crystalline hydrates as defined hereinbefore or hereinafter for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT2.
• the present invention relates to a use of one or more crystalline complexes or crystalline hydrates as defined hereinbefore or hereinafter for preparing a pharmaceutical composition for preventing the degeneration of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells.
• the present invention relates to a method for making one or more crystalline complexes as defined hereinbefore and hereinafter, said method comprising the following steps:
• a yet further aspect of the present invention relates to a method for making one or more crystalline hydrates as defined hereinbefore and hereinafter, said method comprising the following steps:
• FIG. 1 shows an X-ray powder diffractogram of the crystalline complex between the compound A and proline (1 : 1 ).
• the Figure 2 shows the determination of the melting point via DSC of the crystalline complex between the compound A and proline (1 : 1 ).
• the Figure 3 shows an X-ray powder diffractogram of the crystalline hydrate of the compound A.
• the Figure 4 shows the thermoanalysis and determination of the melting point via DSC of the crystalline hydrate of the compound A.
• the present invention relates to a crystalline complex between one or more natural amino acids and the compound A.
• the natural amino acid is present in either its (D) or (L) enantiomeric form, most preferably as the (L) enantiomer.
• crystalline complexes according to this invention are preferred which are formed between one natural amino acid and the compound A, most preferably between the (L) enantiomer of a natural amino acid and the compound A.
• Preferred amino acids according to this invention are selected from the group consisting of phenylalanine and proline, in particular (L)-proline and (L)-phenylalanine.
• the crystalline complex is characterized in that the natural amino acid is proline, in particular (L)-proline.
• the molar ratio of the natural amino acid and the compound A is in the range from about 1 : 1 to 2 : 1 ; most preferably about 1 : 1.
• a preferred crystalline complex according to this invention is a complex (1 : 1 ) between the compound A and proline; in particular of the compound A and L-proline.
• Said crystalline complex of the compound A and proline may be identified and distinguished from other crystalline forms by means of their characteristic X-ray powder diffraction (XRPD) patterns.
• XRPD characteristic X-ray powder diffraction
• Said crystalline complex is preferably characterised by an X-ray powder diffraction pattern that comprises peaks at 16.75, 17.55 and 18.91 degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ i radiation.
• said X-ray powder diffraction pattern comprises peaks at 5.07, 16.75, 17.55, 18.91 and 21.62 degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ i radiation.
• said X-ray powder diffraction pattern comprises peaks at 5.07, 7.28, 16.75, 17.55, 18.91 , 20.34, 21.62 and 28.75 degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ i radiation.
• the crystalline complex of the compound A and proline is characterised by an X-ray powder diffraction pattern, made using CuK ⁇ i radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ) as contained in Table 1.
• Table 1 X-ray powder diffraction pattern of the crystalline complex of the compound A and proline (only peaks up to 30° in 2 ⁇ are listed):
• said crystalline complex is characterised by an X-ray powder diffraction pattern, made using CuK ⁇ i radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ) as shown in Figure 1. Furthermore said crystalline complex is characterised by a melting point of about 197°C ⁇ 3°C (determined via DSC; evaluated as onset-temperature; heating rate 10 K/min). The obtained DSC curve is shown in Figure 2.
• a weight loss of about 1 % of water can be observed by thermal gravimetry. Such a weight loss can for example result by the release of water adsorbed on the surface of said crystals.
• the present invention relates to a crystalline hydrate of the compound A.
• the crystalline hydrate of the compound A may be identified and distinguished from other crystalline forms by means of their characteristic X-ray powder diffraction (XRPD) patterns.
• XRPD characteristic X-ray powder diffraction
• the crystalline hydrate is preferably characterised by an X-ray powder diffraction pattern that comprises peaks at 17.16, 18.53 and 22.94 degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ i radiation.
• said X-ray powder diffraction pattern comprises peaks at 4.53, 13.1 1 , 17.16, 18.53 and 22.94 degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ i radiation.
• said X-ray powder diffraction pattern comprises peaks at 4.53, 13.1 1 , 17.16, 18.53, 19.10, 21.64 and 22.94 degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK ⁇ i radiation.
• the crystalline hydrate is characterised by an X-ray powder diffraction pattern, made using CuK ⁇ i radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.05 degrees 2 ⁇ ) as contained in Table 2.
• Table 2 X-ray powder diffraction pattern of the crystalline hydrate :
• the crystalline hydrate is characterised by an X-ray powder diffraction pattern, made using CuK ⁇ i radiation, which comprises peaks at degrees 2 ⁇ a a ⁇ s Q shhnowwnn i inn F Fiingnumre 33.
• the crystalline hydrate is characterised by a melting point of about 69°C ⁇ 3°C (determined via DSC; evaluated as onset-temperature; heating rate 10 K/min).
• the obtained DSC curve is shown in Figure 4.
• the crystalline hydrate of the compound A is also characterised by thermal gravimetry (TG) with a weight loss of about 6.7 ⁇ 2.3 % water up to approximately 100°C as depicted by the dotted line in Figure 4.
• the observed weight loss indicates that the crystalline hydrate represents a hydrate form with a stoichiometry in the range from about 1 to 2 mol of water per mol of the compound A.
• OED location-sensitive detector
• Canode X-ray source
• Tables 1 and 2 above the values "2 ⁇ [°]” denote the angle of diffraction in degrees and the values "d [A]” denote the specified distances in A between the lattice planes.
• the intensity shown in the Figures 1 and 3 is given in units of cps (counts per second).
• the above described 2 ⁇ values should be considered accurate to ⁇ 0.05 degrees 2 ⁇ . That is to say, when assessing whether a given sample of crystalls of the compound A is a crystalline form in accordance with the invention, a 2 ⁇ value which is experimentally observed for the sample should be considered identical with a characteristic value described above if it falls within ⁇ 0.05 degrees 2 ⁇ of the characteristic value.
• the melting point is determined by DSC (Differential Scanning Calorimetry) using a DSC 821 (Mettler Toledo).
• the weight loss is determined by thermal gravimetry (TG) using a TGA 851 (Mettler Toledo).
• a further aspect of the present invention relates to a method for making the crystalline complex of the present invention as defined hereinbefore and hereinafter, said method comprising the following steps:
• step (a) a solution of the compound A and the one or more natural amino acids in a solvent or a mixture of solvents is prepared.
• the solution is saturated or at least nearly saturated or even supersaturated with respect to the crystalline complex.
• the compound (A) may be dissolved in a solution comprising the one or more natural amino acids or the one or more natural amino acids may be dissolved in a solution comprising the compounds A.
• the compound A is dissolved in a solvent or mixture of solvents to yield a first solution and the one or more natural amino acids are dissolved in a solvent or mixture of solvents to yield a second solution. Thereafter said first solution and said second solution are combined to form the solution according to step (a).
• the molar ratio of the natural amino acid and the compound A in the solution corresponds to the molar ratio of the natural amino acid and the compound A in the crystalline complex to be obtained. Therefore a preferred molar ratio is in the range from about 1 : 1 to 2 : 1 ; most preferably about 1 : 1.
• Suitable solvents are preferably selected from the group consisting of Ci -4 -alkanols, water, ethylacetate, acetonitrile, acetone, diethylether, tetrahydrofuran, and mixture of two or more of these solvents. More preferred solvents are selected from the group consisting of methanol, ethanol, isopropanol, water and mixture of two or more of these solvents, in particular mixtures of one or more of said organic solvents with water.
• Particularly preferred solvents are selected from the group consisting of ethanol, isopropanol, water and mixtures of ethanol and/or isopropanol with water.
• a preferred volume ratio of water : the alkanol is in the range from about 99 : 1 to 1 : 99; more preferably from about 50 : 1 to 1 : 80; even more preferably from about 10 : 1 to 1 : 60.
• the step (a) is carried out at about room temperature (about 20°C) or at an elevated temperature up to about the boiling point of the solvent or mixture of solvents used.
• step (a) and/or in step (b) one or more antisolvents may be added, preferably during step (a) or at the beginning of step (b).
• Water is an example of a suitable antisolvent.
• the amount of antisolvent is preferably chosen to obtain a supersaturated or saturated solution with respect to the crystalline complex.
• step (b) the solution is stored for a time sufficient to obtain a precipitate, i.e. the crystalline complex.
• the temperature of the solution in step (b) is about the same as or lower than in step (a).
• the temperature of the solution is preferably lowered, preferably to a temperature in the range of 20°C to 0°C or even lower.
• the step (b) can be carried out with or without stirring.
• the size, shape and quality of the obtained crystalls can be controlled.
• the crystallization may be induced by methods as known in the art, for example by mechanical means such as scratching or rubbing the contact surface of the reaction vessel for example with a glass rod.
• the (nearly) saturated or supersaturated solution may be inoculated with seed crystalls.
• step (c) the solvent(s) can be removed from the precipitate by known methods as for example filtration, suction filtration, decantation or centrifugation.
• step (d) an excess of the solvent(s) is removed from the precipitate by methods known to the one skilled in the art as for example by reducing the partial pressure of the solvent(s), preferably in vacuum, and/or by heating above ca. 20°C, preferably in a temperature range below 150°C, even more preferably below 100°C.
• a further aspect of the present invention relates to a method for making the crystalline hydrate of the present invention as defined hereinbefore and hereinafter, said method comprising the following steps:
• the terms "saturated” or “nearly saturated” are related to the starting material of the compound A as used in step (a).
• a solution which is saturated with respect to the starting material of the compound A may be supersaturated with respect to its crystalline hydrate.
• Suitable solvents are preferably selected from the group consisting of C- M -alkanols, water, ethylacetate, acetonitrile, acetone, diethylether, tetrahydrofuran, and mixture of two or more of these solvents.
• More preferred solvents are selected from the group consisting of methanol, ethanol, isopropanol, water and mixture of two or more of these solvents, in particular mixtures of one or more of said organic solvents with water.
• Particularly preferred solvents are selected from the group consisting of water, ethanol, isopropanol and mixtures of ethanol and/or isopropanol with water.
• a preferred volume ratio of water : the alkanol is in the range from about 1 : 1 to 90 : 1 ; more preferably from about 2 : 1 to 10 : 1.
• the proviso for the starting material of the compound A and/or the solvent and mixtures of solvents is that these contain an amount of H 2 O which is at least the quantity required to form a hydrate of the compound A; in particular at least 1 mol, preferably at least 1.5 mol of water per mol of compound A. Even more preferably the amount of water is at least 2 mol of water per mol of compound A.
• a water content of the solvent(s) is not mandatory.
• the step (a) is carried at about room temperature (about 20°C) or at an elevated temperature up to about the boiling point of the solvent or mixture of solvents used.
• step (a) and/or in step (b) one or more antisolvents may be added, preferably during step (a) or at the beginning of step (b).
• Water is an example of a suitable antisolvent.
• the amount of antisolvent is preferably chosen to obtain a supersaturated or nearly supersaturated solution with respect to the crystalline hydrate.
• step (b) the solution is stored for a time sufficient to obtain a precipitate.
• the temperature of the solution in step (b) is about the same as or lower than in step (a).
• the temperature of the solution containing the compound A is preferably lowered, preferably to a temperature in the range of 20°C to 0°C or even lower.
• the step (b) can be carried out with or without stirring.
• the size, shape and quality of the obtained crystalls can be varied.
• the crystallization may be induced by methods as known in the art, for example by scratching or rubbing.
• the (nearly) saturated or supersaturated solution may be inoculated with seed crystalls.
• step (c) the solvent(s) can be removed from the precipitate by known methods as for example filtration, suction filtration, decantation or centrifugation.
• step (d) an excess of the solvent(s) is removed from the precipitate by methods known to the one skilled in the art as for example by reducing the partial pressure of the solvent(s), preferably in vacuum, and/or by heating above ca. 20°C, preferably in a temperature range below 65°C, even more preferably below 50°C.
• the compound A may be synthesized by methods as specifically and/or generally described or cited in the international application WO 2005/092877. Furthermore the biological properties of the compound A may be investigated as it is described in the international application WO 2005/092877 which in its enterity is incorporated herein by reference.
• the crystalline complex and crystalline hydrate in accordance with the invention are preferably employed as drug active substances in substantially pure form, that is to say, essentially free of other crystalline forms of the compound A. Nevertheless, the invention also embraces the crystalline complex or the crystalline hydrate in admixture with another crystalline form or forms. Should the drug active substance be a mixture of crystalline forms, it is preferred that the substance comprises at least 50%-weight of the crystalline complex as described herein or at least 50%-weight of the crystalline hydrate as descrbied herein.
• the crystalline complex according to the invention and the crystalline hydrate according to this invention are suitable for the preparation of pharmaceutical compositions for the treatment and/or preventative treatment of all those conditions or diseases which may be affected by the inhibition of the SGLT activity, particularly the SGLT-2 activity. Therefore, the crystalline complex according to the invention and the crystalline hydrate according to this invention are particularly suitable for the preparation of pharmaceutical compositions for prevention or treatment of diseases, particularly metabolic disorders, or conditions such as type 1 and type 2 diabetes mellitus, complications of diabetes (such as e.g.
• retinopathy retinopathy, nephropathy or neuropathies, diabetic foot, ulcers, macroangiopathies
• metabolic acidosis or ketosis reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, oedema and hyperuricaemia.
• the crystalline complex according to the invention and the crystalline hydrate according to this invention are also suitable for the preparation of pharmaceutical compositions for preventing beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta cells.
• the crystalline complex according to the invention and the crystalline hydrate according to this invention are also suitable for the preparation of pharmaceutical compositions for improving or restoring the functionality of pancreatic cells, and also of increasing the number and size of pancreatic beta cells.
• the crystalline complex according to the invention and the crystalline hydrate according to this invention may also be used for the preparation of pharmaceutical compositions usefull as diuretics or antihypertensives and suitable for the prevention and treatment of acute renal failure.
• the crystalline complex according to the invention and the crystalline hydrate according to this invention are suitable for the preparation of pharmaceutical compositions for the prevention or treatment of diabetes, particularly type 1 and type 2 diabetes mellitus, and/or diabetic complications.
• the dosage required to achieve the corresponding activity for treatment or prevention usually depends on the patient, the nature and gravity of the illness or condition and the method and frequency of administration and is for the patient's doctor to decide.
• the dosage may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in each case administered 1 to 4 times a day.
• the pharmaceutical compositions according to this invention preferably comprise the crystalline complex according to the invention or the crystalline hydrate according to this invention together with one or more inert conventional carriers and/or diluents.
• Such pharmaceutical compositions may be formulated as conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
• a solution of 86.2 g (5-bromo-2-chloro-phenyl)-(4-methoxy-phenyl)-methanone and 101.5 mL triethylsilane in 75 mL dichloromethane and 150 mL acetonitrile is cooled to 10°C.
• 25 with stirring 50.8 mL of boron trifluoride etherate are added so that the temperature does not exceed 20 °C.
• the solution is stirred for 14 h at ambient temperature, before another 9 mL triethylsilane and 4.4 mL boron trifluoride etherate are added.
• the solution is stirred for a further 3 h at 45-50 °C and then cooled to ambient temperature.
• a solution of 14.8 g 4-bromo-1-chloro-2-(4-methoxy-benzyl)-benzene in 150 ml_ dichloromethane is cooled in an ice bath. Then 50 ml. of a 1 M solution of boron tribromide in dichloromethane are added, and the solution is stirred for 2 h at ambient temperature. The solution is then cooled in an ice bath again, and saturated potassium carbonate solution is added dropwise. At ambient temperature the mixture is adjusted with aqueous 1 M hydrochloric acid to a pH of 1 , the organic phase is separated and the aqueous phase is extracted another three times with ethyl acetate.
• Aqueous sodium hydrogen carbonate solution is added to the remaining solution that is extracted then four times with ethyl acetate.
• the organic phases are dried over sodium sulfate and evaporated down.
• the residue is dissolved in 30 mL acetonitrile and 30 mL dichloromethane and the solution is cooled to -10 °C.
• 4.4 mL triethylsilane 2.6 mL boron trifluoride etherate are added dropwise so that the temperature does not exceed -5 °C.
• the solution is stirred for another 5 h at -5 to -10 °C and then quenched by the addition of aqueous sodium hydrogen carbonate solution.
• the organic phase is separated off and the aqueous phase is extracted four times with ethyl acetate.
• the combined organic phase are dried over sodium sulfate, the solvent is removed and the residue is purified using silica gel.
• the product then obtained is an approx. 6:1 mixture of ⁇ / ⁇ which can be converted into the pure ⁇ -anomer by global acetylation of the hydroxy groups with acetic anhydride and pyridine in dichloromethane and recrystallizing the product from ethanol.
• the product thus obtained is converted into the title compound by reacting in methanol with 4 M potassium hydroxide solution.
• Residual solvent is removed by storing the crystals at elevated temperature (50 to 60 °C) for about 4 h to yield 1 19 mg of the crystalline 1 :1 complex between L-proline and 1-chloro-4-( ⁇ -D-glucopyranos-1-yl)-2-(4- ethynyl-benzyl)-benzene.
• the obtained crystaline complex is characterized by a X-ray powder diffraction pattern as contained in Table 1 and as depicted in Fig. 1. Furthermore the resulting crystalline complex is characterized by a melting point of 197 °C ⁇ 3 °C.
• the obtained crystaline hydrate is characterized by a X-ray powder diffraction pattern as contained in Table 2 and as depicted in Fig. 3. Furthermore the resulting crystalline complex is characterized by a melting point of 69 °C ⁇ 3 °C.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Obesity (AREA)
• Heart & Thoracic Surgery (AREA)
• Biotechnology (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Urology & Nephrology (AREA)
• Child & Adolescent Psychology (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Pyrane Compounds (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37478909

Family Applications (1)

Country Status (19)

Cited By (62)

Families Citing this family (11)

Citations (3)

Family Cites Families (64)

• 2006
  • 2006-09-07 TW TW095133001A patent/TW200745075A/zh unknown
  • 2006-09-07 CN CNA2006800287058A patent/CN101238112A/zh active Pending
  • 2006-09-07 KR KR1020087008490A patent/KR20080053369A/ko not_active Withdrawn
  • 2006-09-07 MX MX2008002457A patent/MX2008002457A/es not_active Application Discontinuation
  • 2006-09-07 ES ES06793305T patent/ES2358051T3/es active Active
  • 2006-09-07 JP JP2008529633A patent/JP5345846B2/ja active Active
  • 2006-09-07 DE DE602006018961T patent/DE602006018961D1/de active Active
  • 2006-09-07 AT AT06793305T patent/ATE491700T1/de active
  • 2006-09-07 CA CA002621314A patent/CA2621314A1/en not_active Withdrawn
  • 2006-09-07 EP EP06793305A patent/EP1926720B1/en active Active
  • 2006-09-07 AU AU2006289093A patent/AU2006289093A1/en not_active Abandoned
  • 2006-09-07 US US11/470,684 patent/US8507450B2/en active Active
  • 2006-09-07 BR BRPI0615882-0A patent/BRPI0615882A2/pt not_active IP Right Cessation
  • 2006-09-07 RU RU2008113050/04A patent/RU2008113050A/ru not_active Application Discontinuation
  • 2006-09-07 WO PCT/EP2006/066107 patent/WO2007028814A1/en not_active Ceased
  • 2006-09-07 NZ NZ566787A patent/NZ566787A/en unknown
  • 2006-09-08 AR ARP060103906A patent/AR056055A1/es unknown
• 2008
  • 2008-01-23 ZA ZA200800681A patent/ZA200800681B/xx unknown
  • 2008-03-05 IL IL189950A patent/IL189950A0/en unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events